Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 8/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25355866 | 1.00 | CYP1A2 (0.49) | CYP1A2CYP2C9ATRPIK3CBTRPM8 | |
| SCHEMBL30455146 | 0.83 | TRPM8 (0.56) | CYP1A2CYP2C9TRPM8LMNAMAPT | |
| SCHEMBL14349473 | 0.83 | TRPM8 (0.56) | CYP1A2CYP2C9TRPM8LMNAMAPT | |
| SCHEMBL31652152 | 0.82 | EPHX2 (0.51) | — | |
| SCHEMBL22755279 | 0.81 | KMT2A (0.53) | LMNAMAPT | |
| SCHEMBL25359834 | 0.79 | ATR (0.48) | ATRATRIPLRRK2 | |
| SCHEMBL25359841 | 0.79 | ATR (0.48) | ATRATRIPLRRK2 | |
| SCHEMBL30453962 | 0.79 | ATR (0.48) | ATRATRIPLRRK2 | |
| SCHEMBL10094264 | 0.77 | CYP1A2 (0.52) | CYP1A2CYP2C9TRPM8LMNAPIK3CA | |
| SCHEMBL3242228 | 0.75 | PIK3CA (0.44) | CYP1A2CYP2C9ATRTRPM8ATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |